Lixisenatide
FDA ApprovedAlso known as: Adlyxin, Lyxumia
GLP-1 AgonistLast reviewed: April 28, 2026
A once-daily GLP-1 receptor agonist FDA-approved for type 2 diabetes. Shorter-acting than semaglutide, with a stronger effect on postprandial glucose. Also available in a fixed-ratio combination with insulin glargine (Soliqua).
Mechanism of Action
Activates GLP-1 receptors, stimulating glucose-dependent insulin secretion and suppressing glucagon. Its shorter duration of action produces a more pronounced effect on gastric emptying and postprandial glucose compared to longer-acting GLP-1 agonists.
Common Uses
- Type 2 diabetes (adjunct to diet and exercise)
- Postprandial glucose control
- Combined with basal insulin (Soliqua)
Known Risks
- Nausea and vomiting (common, usually transient)
- Diarrhea
- Headache
- Hypoglycemia when combined with sulfonylureas
- Pancreatitis (rare)
Regulatory Status
FDA-approved as Adlyxin (2016) for type 2 diabetes. Also available as Soliqua 100/33 (fixed-ratio combination with insulin glargine). Less weight loss than semaglutide but better postprandial control.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
10 mcg for 14 days, then 20 mcg
Frequency
Once daily (within 1 hour before first meal)
Cycle Length
Ongoing
Inject in abdomen, thigh, or upper arm. Take within 1 hour before the first meal of the day. Shorter-acting than semaglutide — better for postprandial spikes.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.